Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
All the ways Marjorie Taylor Greene has shifted her approach lately — and why Trump is 'surprised at her' - 2Tesla Germany Registrations Quadruple to 9,252 Vehicles in Best March Ever
- 3South Korea to End Bear Bile Farming and Find New Homes for the 200 Bears Stuck in the Industry
- 4The Iconic, Instantly Recognizable Plastic Chair That's Known All Around The World
- 5Find the Advantages of Innovative Leisure activities: Supporting Creative mind and Self-Articulation
- 6 Trail blazing Bicycles for Rough terrain Undertakings
- Apollo's impatient old-timers are rooting for NASA's return to the moon with Artemis II launch
- NASA’s Artemis II launch leaves Americans in awe: ‘We’re going to the frickin’ moon!’
- I took my shoes off and went for a barefoot hike. I couldn’t believe what happened next
- Idris Elba is the king of the stress-watch
- McDonald's is bringing two 'KPop Demon Hunters' meals to McDonald's. Here's what they include and when they launch.
- High velocity Internet services for Metropolitan Regions
- Scientists train to dive beneath polar ice as climate change warms the Arctic and Antarctica
- Amy Poehler's podcast is a hit. It's also a Trojan horse for talking about women and aging.
